Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

Atilla E., Sahin U., Atilla P. A., Merter M., PEKER E., CEYHAN K., ...More

Hematology/ Oncology and Stem Cell Therapy, vol.12, no.4, pp.220-225, 2019 (Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.1016/j.hemonc.2018.02.001
  • Journal Name: Hematology/ Oncology and Stem Cell Therapy
  • Journal Indexes: Scopus
  • Page Numbers: pp.220-225
  • Keywords: Allogeneic stem cell transplantation, Graft versus leukemia effect, Primary central nervous system lymphoma
  • Ankara University Affiliated: Yes

Abstract

© 2018 King Faisal Specialist Hospital & Research CentrePrimary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether graft versus lymphoma effect can work in PCNSL patients. Here, we present a relapsed refractory PCNSL case treated by allo-HCT.